Reversal of NASH Fibrosis with Pharmacotherapy

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2019 Aug 1

PMID 31363910

Citations 9

Authors

Joseph J Alukal

Paul J Thuluvath

Affiliations

Soon will be listed here.

Abstract

NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.

Citing Articles

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.

Rabiu L, Zhang P, Afolabi L, Saliu M, Dabai S, Suleiman R J Gastroenterol. 2024; 59(12):1053-1078.

PMID: 39400718 DOI: 10.1007/s00535-024-02157-0.

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.

Mohammed O, Attia H, Mohamed B, Elbaset M, Fayed H J Pharm Pharm Sci. 2023; 26:11808.

PMID: 38022905 PMC: 10662312. DOI: 10.3389/jpps.2023.11808.

Growth hormone and nonalcoholic fatty liver disease.

Ma I, Stanley T Immunometabolism (Cobham). 2023; 5(3):e00030.

PMID: 37520312 PMC: 10373851. DOI: 10.1097/IN9.0000000000000030.

New Drugs for Hepatic Fibrosis.

Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X Front Pharmacol. 2022; 13:874408.

PMID: 35770089 PMC: 9234287. DOI: 10.3389/fphar.2022.874408.

Therapeutic potentials of fasudil in liver fibrosis.

Xi Y, Xu P World J Gastroenterol. 2021; 27(45):7859-7861.

PMID: 34963748 PMC: 8661378. DOI: 10.3748/wjg.v27.i45.7859.

References

Friedman S . Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1):125-72. PMC: 2888531. DOI: 10.1152/physrev.00013.2007. View

Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y . Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4):431-42. DOI: 10.1038/nbt1396. View

Wang Y, Chen W, Wang M, Yu D, Forman B, Huang W . Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48(5):1632-43. PMC: 3056574. DOI: 10.1002/hep.22519. View

Argo C, Northup P, Al-Osaimi A, Caldwell S . Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009; 51(2):371-9. DOI: 10.1016/j.jhep.2009.03.019. View

Choi S, Omenetti A, Witek R, Moylan C, Syn W, Jung Y . Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2009; 297(6):G1093-106. PMC: 2850083. DOI: 10.1152/ajpgi.00292.2009. View

Tamura Y, Sugimoto M, Murayama T, Minami M, Nishikaze Y, Ariyasu H . C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb. 2010; 17(3):219-28. DOI: 10.5551/jat.3368. View

Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N . Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. PMC: 2928471. DOI: 10.1056/NEJMoa0907929. View

Wong V, Wong G, Choi P, Chan A, Li M, Chan H . Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59(7):969-74. DOI: 10.1136/gut.2009.205088. View

Zingarelli B, Piraino G, Hake P, OConnor M, Denenberg A, Fan H . Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am J Pathol. 2010; 177(4):1834-47. PMC: 2947279. DOI: 10.2353/ajpath.2010.091010. View

10.

Younossi Z, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R . Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53(6):1874-82. DOI: 10.1002/hep.24268. View

11.

Omenetti A, Diehl A . Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol. 2011; 27(3):268-75. PMC: 3636549. DOI: 10.1097/MOG.0b013e32834550b4. View

12.

Alkhouri N, Carter-Kent C, Feldstein A . Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2011; 5(2):201-12. PMC: 3119461. DOI: 10.1586/egh.11.6. View

13.

Ishida Y, Nagata K . Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol. 2011; 499:167-82. DOI: 10.1016/B978-0-12-386471-0.00009-2. View

14.

Gupta S, Takebe N, LoRusso P . Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2011; 2(4):237-50. PMC: 3126020. DOI: 10.1177/1758834010366430. View

15.

Tyagi S, Gupta P, Saini A, Kaushal C, Sharma S . The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2012; 2(4):236-40. PMC: 3255347. DOI: 10.4103/2231-4040.90879. View

16.

Xie G, Choi S, Syn W, Michelotti G, Swiderska M, Karaca G . Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut. 2012; 62(2):299-309. PMC: 3595101. DOI: 10.1136/gutjnl-2011-301494. View

17.

Mudaliar S, Henry R, Sanyal A, Morrow L, Marschall H, Kipnes M . Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013; 145(3):574-82.e1. DOI: 10.1053/j.gastro.2013.05.042. View

18.

Traber P, Chou H, Zomer E, Hong F, Klyosov A, Fiel M . Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013; 8(10):e75361. PMC: 3793988. DOI: 10.1371/journal.pone.0075361. View

19.

Barreyro F, Holod S, Finocchietto P, Camino A, Aquino J, Avagnina A . The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2014; 35(3):953-66. DOI: 10.1111/liv.12570. View

20.

Safadi R, Konikoff F, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T . The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12(12):2085-91.e1. DOI: 10.1016/j.cgh.2014.04.038. View